MX389359B - Uso terapeutico de la proteina de union a neurotrofina p75ntr. - Google Patents

Uso terapeutico de la proteina de union a neurotrofina p75ntr.

Info

Publication number
MX389359B
MX389359B MX2017000698A MX2017000698A MX389359B MX 389359 B MX389359 B MX 389359B MX 2017000698 A MX2017000698 A MX 2017000698A MX 2017000698 A MX2017000698 A MX 2017000698A MX 389359 B MX389359 B MX 389359B
Authority
MX
Mexico
Prior art keywords
binding protein
therapeutic use
neurotrophin binding
protein p75ntr
p75ntr
Prior art date
Application number
MX2017000698A
Other languages
English (en)
Other versions
MX2017000698A (es
Inventor
Simon Westbrook
Original Assignee
Levicept Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Levicept Ltd filed Critical Levicept Ltd
Publication of MX2017000698A publication Critical patent/MX2017000698A/es
Publication of MX389359B publication Critical patent/MX389359B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/644—Transferrin, e.g. a lactoferrin or ovotransferrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente invención se refiere a una proteína de unión a la neurotrofina p75NTR (p75NTR(NBP)) para usarse en el tratamiento de osteoartritis, en donde la p75NTF(NBP)tiene la secuencia de aminoácidos de conformidad con la SEQ ID NO: 3, y en donde la P75NTR(NBP) se une a cualquiera de NGF, BDNF, NT3 o NT4/5 con una afinidad de unión (Kd) de entre aproximadamente 5 pM aproximadamente 5 nM como medido por resonancia de plasmón de superficie a 20°C
MX2017000698A 2014-07-17 2015-07-17 Uso terapeutico de la proteina de union a neurotrofina p75ntr. MX389359B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1412748.4A GB201412748D0 (en) 2014-07-17 2014-07-17 Therapeutic use of P75NTR neurotrophin binding protein
PCT/GB2015/052083 WO2016009222A1 (en) 2014-07-17 2015-07-17 Therapeutic use of p75ntr neurotrophin binding protein

Publications (2)

Publication Number Publication Date
MX2017000698A MX2017000698A (es) 2017-04-27
MX389359B true MX389359B (es) 2025-03-20

Family

ID=51494769

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017000698A MX389359B (es) 2014-07-17 2015-07-17 Uso terapeutico de la proteina de union a neurotrofina p75ntr.

Country Status (17)

Country Link
US (2) US11339202B2 (es)
EP (1) EP3169347A1 (es)
JP (3) JP2017527303A (es)
KR (3) KR20240161225A (es)
CN (1) CN108137668A (es)
AU (3) AU2015288918B2 (es)
BR (1) BR112017000833A2 (es)
CA (1) CA2953061C (es)
EA (1) EA201700057A1 (es)
GB (1) GB201412748D0 (es)
HK (1) HK1256712A1 (es)
IL (1) IL249535B (es)
MX (1) MX389359B (es)
NZ (1) NZ727446A (es)
SG (1) SG11201700056RA (es)
WO (1) WO2016009222A1 (es)
ZA (1) ZA201608675B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2014007870A0 (en) 2012-03-14 2014-08-31 Levicept Ltd Therapeutic use of P75NTR neurotrophin binding protein
GB201316592D0 (en) * 2013-09-18 2013-10-30 Levicept Ltd Fusion protein
GB201412748D0 (en) 2014-07-17 2014-09-03 Levicept Ltd Therapeutic use of P75NTR neurotrophin binding protein
GB201504691D0 (en) 2015-03-19 2015-05-06 Levicept Ltd Fusion protein
US11608371B1 (en) 2021-10-21 2023-03-21 Petmedix Ltd Therapeutic molecules
GB202307936D0 (en) * 2023-05-26 2023-07-12 Levicept Ltd Fusion protein
GB202307932D0 (en) * 2023-05-26 2023-07-12 Levicept Ltd Fusion protein
WO2025184422A1 (en) * 2024-02-27 2025-09-04 Levicept Ltd Fusion protein and uses thereof
WO2025181485A1 (en) 2024-02-27 2025-09-04 Levicept Limited P75 neurotrophin receptor-fc fusion protein for use in pain therapy
WO2025181486A1 (en) 2024-02-27 2025-09-04 Levicept Limited Process for manufacturing of glycosylated p75ntr-fc fusion protein
WO2025262427A1 (en) 2024-06-19 2025-12-26 Levicept Limited Injectable formulation

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9022648D0 (en) 1990-10-18 1990-11-28 Charing Cross Sunley Research Polypeptide and its use
FR2686900B1 (fr) * 1992-01-31 1995-07-21 Rhone Poulenc Rorer Sa Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant.
US7217798B2 (en) 2003-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of Fc-fusion protein serum half-lives by mutagenesis
US7569364B2 (en) * 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
ATE470454T1 (de) * 2004-09-13 2010-06-15 Genzyme Corp Multimere konstrukte
CN101160322A (zh) * 2005-01-28 2008-04-09 阿波罗生命科学有限公司 分子及其嵌合分子
WO2006079176A1 (en) 2005-01-28 2006-08-03 Apollo Life Sciences Limited Molecules and chimeric molecules thereof
JPWO2007026567A1 (ja) 2005-08-30 2009-03-05 国立大学法人 千葉大学 ｐ７５ＮＴＲ阻害剤を有効成分として含有する鎮痛剤
US20070243132A1 (en) 2005-12-22 2007-10-18 Apollo Life Sciences Limited Transdermal delivery of pharmaceutical agents
US8309088B2 (en) * 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
US20100061981A1 (en) * 2008-08-15 2010-03-11 The Salk Institute For Biological Studies p75NTR MEDIATES EPHRIN-A REVERSE SIGNALING
CA2787099A1 (en) * 2009-03-30 2010-10-14 Anice C. Lowen Influenza virus hemagglutinin polypeptides containing stem domains, vaccines and uses thereof
CN102459337B (zh) * 2009-05-04 2015-05-20 雅培研究有限责任公司 具有增强的体内稳定性的抗神经生长因子(ngf)抗体
CN102233128B (zh) 2010-11-26 2013-04-17 王延江 一种p75NTR-ECD在防治阿尔茨海默病药物中应用
ITRM20110024A1 (it) 2011-01-24 2012-07-25 Consiglio Nazionale Ricerche Uso di antagonisti del recettore p75ntr e/o di agonisti del recettore trka per il trattamento delle malattie infiammatorie croniche.
TWI476001B (zh) 2011-12-26 2015-03-11 Ind Tech Res Inst 三倍體Ｆｃ融合蛋白及其用途
CN102586313A (zh) 2012-03-05 2012-07-18 中国人民解放军第三军医大学野战外科研究所 p75NTR-ED-Fc融合蛋白的制备方法及其在损伤中枢神经再生与功能恢复中的应用
AP2014007870A0 (en) * 2012-03-14 2014-08-31 Levicept Ltd Therapeutic use of P75NTR neurotrophin binding protein
EP2674439B1 (en) * 2012-06-13 2017-02-01 Rottapharm Biotech S.r.l. Anti-TrkA antibodies, derivatives and uses thereof
GB201316592D0 (en) * 2013-09-18 2013-10-30 Levicept Ltd Fusion protein
GB201412748D0 (en) 2014-07-17 2014-09-03 Levicept Ltd Therapeutic use of P75NTR neurotrophin binding protein
GB201504691D0 (en) 2015-03-19 2015-05-06 Levicept Ltd Fusion protein

Also Published As

Publication number Publication date
JP2017527303A (ja) 2017-09-21
JP2021177766A (ja) 2021-11-18
KR20230004967A (ko) 2023-01-06
KR20170062442A (ko) 2017-06-07
CN108137668A (zh) 2018-06-08
EP3169347A1 (en) 2017-05-24
BR112017000833A2 (pt) 2020-07-07
US20170204156A1 (en) 2017-07-20
SG11201700056RA (en) 2017-02-27
US11339202B2 (en) 2022-05-24
AU2015288918A1 (en) 2017-01-12
CA2953061C (en) 2024-09-10
MX2017000698A (es) 2017-04-27
NZ727446A (en) 2022-02-25
KR20240161225A (ko) 2024-11-12
IL249535B (en) 2021-01-31
EA201700057A1 (ru) 2017-06-30
CA2953061A1 (en) 2016-01-21
JP2024097041A (ja) 2024-07-17
WO2016009222A1 (en) 2016-01-21
GB201412748D0 (en) 2014-09-03
JP7365378B2 (ja) 2023-10-19
AU2015288918B2 (en) 2021-02-25
HK1256712A1 (zh) 2019-10-04
ZA201608675B (en) 2019-11-27
AU2024205039A1 (en) 2024-09-19
AU2021201611A1 (en) 2021-04-01
US20230093211A1 (en) 2023-03-23
IL249535A0 (en) 2017-02-28

Similar Documents

Publication Publication Date Title
MX389359B (es) Uso terapeutico de la proteina de union a neurotrofina p75ntr.
CY1121347T1 (el) Πρωτεϊνη συντηξης
CY1119213T1 (el) Πρωτεϊνη p75ntr συνδεσης νευροτροφινης για θεραπευτικη χρηση
IL282663A (en) Bt1718 for use in treating cancer
BR112017024899A2 (pt) proteínas de ligação trispecíficas e métodos de uso.
PT3060237T (pt) Proteína de reprogramação modificada para utilização no tratamento de um cancro
EA201892386A1 (ru) Химерные нейротоксины
MX375032B (es) Proteínas de unión y métodos para utilizarlas.
UY36021A (es) Proteìnas fc multimèricas
MX2019008521A (es) Heterociclos triciclicos como inhibidores de la proteina bet.
IL276063A (en) Medicinal compounds that bind to lag3 and pd1
GEP20227343B (en) Anti-lag3 antibodies and antigen-binding fragments
EA201690314A1 (ru) Анти-garp-белок и его применения
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
EP3578165A4 (en) IRREGULARITY CORRECTION COSMETIC PRODUCT
EA201790334A1 (ru) Конъюгаты анти-cdh6 антитела с лекарственным средством
EA201692529A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
DK3197472T3 (da) Rekombinante phe-frie proteiner til anvendelse i behandlingen af phenylketonuri
HRP20190412T1 (hr) Konstrukti proteina uspa2 i njihova upotreba
BR112017008799A2 (pt) composições de apilimod e métodos de uso das mesmas no tratamento de câncer renal
PT3478719T (pt) Uso de anticorpos anti-esclerostina no tratamento da osteogénese imperfeita
PT3303384T (pt) Moléculas de ligação neutralizantes anti-influenza e suas utilizações
EA201891299A1 (ru) Терапевтические антитела к cd9
MX2017001038A (es) Variantes de proteina de unión al factor h y metodos de uso de estas.
EA201692395A1 (ru) Новые соединения